AMDL Inc. announced the launch of a novel brand name for its DR-70 (FDP) in vitro diagnostic cancer test. With this announcement, the company will manufacture, market, and sell DR-70 under the more consumer-friendly, trademarked brand name Onko-Sure.
Mr. Douglas MacLellan, Chairman and CEO of AMDL stated, Over the past six months AMDL has been executing a very aggressive commercialization strategy for DR-70, which is progressing at a faster pace than originally expected. With several key distribution and collaboration partnerships under our belt, and more in the pipeline, we feel timing is optimal to establish a uniform and more consumer-friendly brand name for DR-70. The Onko-Sure identity represents a key milestone in AMDL’s strategy for building and harmonizing an international business for this invaluable asset. We want Onko-Sure to become the undisputed global brand for in vitro diagnostic cancer testing.
The company is instilling a new tag line The Power of Knowing which communicates to cancer patients and their physicians the test is effective in assessing the importance of knowing whether a patient’s cancer is progressing during treatment or is in remission.
By measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP), AMDL’s Onko-Sure in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers.
The test is approved by Health and Canada as a lung cancer detection and monitoring tool and by US Food and Drug Administration (US FDA) for the monitoring of colorectal cancer. In addition the test is approved in Australia, Taiwan and Europe, where it has obtained the CE mark approval, as a general cancer screen. Throughout FY2009 AMDL continues to expand product commercialization into international markets based on other pending regulatory approvals. AMDL also plans to file for marketing approvals in other areas of the world.
In 2009 the Company initiated an aggressive international commercialization plan for the Onko-Sure cancer test and has long-term plans to grow its IVD division into a multi-million dollar operation that complements its strong China-based pharmaceuticals division.
Mr. MacLellan continued, We have achieved multiple key milestones this year that have never before been set in our IVD division. The adoption of the new Onko-Sure brand, combined with on-going program investments such that include collaboration with Mayo Clinic and the signing of various marketing, distribution and sales partnerships, reinforces the Company’s commitment to growing our Tustin operations and ultimately achieving profitability.